Amgen (AMGN): FY25 Q2 earnings call, Aug 5, 2025

Tue, Aug 5Earnings callSpeaker-labelled transcriptAmgen

No Kalshi or Polymarket word markets were listed for Amgen’s Aug 5, 2025 earnings call (FY25 Q2). The transcript is searchable below (quotes of at most 25 words).

Updated

Transcript

quotes of at most 25 words

Speaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.

6 matches for “Oral”; 3 quoted, at least 25 words apart.

Luca Issianalystqa

…some very encouraging data for orforglipron at ADA, which is obviously an oral small molecule. What's Amgen's appetite to augment your current offering vis-a-vis by…

Murdo Gordoncompanyqa

…market going forward. As Bob said, we are interested in looking at orals, and that comes from us seeing orals constituting a decent portion of…

Murdo Gordoncompanyqa

…can benefit from that in important ways with outcomes. So looking at the orals very closely, but excited about our flagship product that we're developing.

Agents: this page as TSV at /api/v1/appearances/amgen:2025-08-05:earnings_call · words: /api/v1/brief?appearance=amgen:2025-08-05:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP